The prevalence and severity of insomnia symptoms during COVID-19: A global systematic review and individual participant data meta-analysis

ALRASHEED, MAHA M.; FEKIH-ROMDHANE, FETEN; JAHRAMI, HAITHAM; PIRES, GABRIEL NATAN; SAIF, ZAHRA; ALENEZI, AHMAD F.; HUMOOD, ALI; CHEN, WEN; DAI, HAIJIANG; BRAGAZZI, NICOLA; PANDI-PERUMAL, SEITHIKURIPPU R.; BAHAMMAM, AHMED S.; VITIELLO, MICHAEL V.; OLASENI, AO; MIRANDA, AR; URZÚA, A; ALSHAHRANI, AH; SOUADKA, A; SCOTTA, ANA VERÓNICA; SAMANIEGO, A; LAHIRI, A; GARAY, A; CHAKRABORTY, A; VELIOGLUI, A; D'ATRI, A.

SLEEP MEDICINE

ELSEVIER SCIENCE BV

Año: 2022 vol. 100 p. 7 - 7

1389-9457

ntroduction: There have been no previous meta-analytic studies that have looked at the prevalence of insomnia symptoms in different COVID-19 groups using a single assessment instrument to evaluate insomnia symptoms while maintaining data homogeneity. The current review´s associated goal is to undertake an individual participant data (IPD) analysis to further investigate past meta-analyses, a method that has been shown to be more robust than standard meta-analyses. Meethods: Only studies that used the Insomnia Severity Index (ISI) to assess insomnia are used in this analysis. The IPDMA was performed and registered in PROSPERO in compliance with the PRISMA IPD Statement (CRD42021275817). From November 2019 to August 2021, researchers explored seventeen databases and six preprint services for relevant studies. Results: The pooled estimate of insomnia symptoms (subthreshold and clinically significant) was 52.57%. An estimated 16.66% of the population suffered from clinically significant i